Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Radiopharm Theranostics Limited Sponsored ADR ( (RADX) ) just unveiled an update.
On October 1, 2025, Radiopharm Theranostics announced receiving a positive recommendation from the Data Safety and Monitoring Committee to accelerate the Phase 1 ‘HEAT’ clinical trial of its radiotherapeutic asset, 177Lu-RAD202. This advancement allows the trial to progress to a higher dose level of 75mCi in patients with HER2-positive advanced solid tumors, reflecting promising initial safety signals and the potential to offer new treatment options for these cancers. The trial’s acceleration marks a significant step in the company’s efforts to identify the optimal Phase 2 dose, with data from the first two cohorts expected by the end of 2025.
The most recent analyst rating on (RADX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.
More about Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative radiopharmaceutical products for diagnostic and therapeutic applications in oncology. The company is listed on both the Australian Securities Exchange and NASDAQ and has a pipeline that includes distinct platform technologies such as peptides, small molecules, and monoclonal antibodies for treating various solid tumor cancers.
Average Trading Volume: 30,035
Technical Sentiment Signal: Strong Buy
Current Market Cap: $45.27M
For detailed information about RADX stock, go to TipRanks’ Stock Analysis page.